针对复发性/耐药性B-ALL的新型免疫疗法点:文学综述
Jeffery White1, Mitchell Clark1, Elizabeth Tuller1
1Texas A and M College of Medicine, College Station, TX.
Journal of the Association of Genetic Technologists
|September 2, 2024
概括
新的仿真抗原受体 (CAR T细胞) 标对于治疗复发性/耐药性B细胞急性淋巴细胞白血病 (B-ALL) 在CD19治疗失败时至关重要. 本综述探讨了改善B-ALL免疫疗法的CD371等新目标.
科学领域:
- 儿科瘤学 儿科瘤学
- 免疫治疗是一种免疫疗法.
- 癌症遗传学 癌症遗传学
背景情况:
- 乙细胞急性淋巴细胞白血病 (B-ALL) 是美国主要的儿童癌症.
- 化学抗原受体 (CAR T-细胞) 免疫疗法已经推进了B-ALL治疗.
- 由于CD19抗原逃逸的复发需要新的治疗点.
研究的目的:
- 对复发性/耐火性B-ALL.的已确定的和潜在的CAR T细胞点进行审查.
- 专注于特定的B-ALL子组:KMT2A,IKZF1相关的和DUX4r.
- 突出基因和蛋白质组方法来识别新的B-ALL目标.
主要方法:
- 文献综述侧重于B-ALL.的遗传和蛋白质组分析.
- 具体目标的检查:冠状素硫酸盐蛋白质甘氨酸4,CD72,胸膜 stromal 淋巴蛋白受体和CD371.
- 讨论新兴的CAR T细胞策略和其他疗法.
主要成果:
- 丁硫酸盐蛋白质甘氨酸4被确定为混合血统重新排列白血病的标.
- 在特定的B-ALL亚群中,CD72和胸膜 stromal lymphopoietin受体是潜在的标.
- CD371被提出为DUX4r B-ALL的有希望的标,得到了急性髓性白血病数据的支持.
结论:
- 新型CAR T细胞点对于克服复发性/耐火性B-ALL中的抗原逃逸至关重要.
- 向CD371为DUX4r B-ALL治疗提供了一个潜在的新途径.
- 对创新免疫疗法的持续研究对于改善患者的治疗结果至关重要.
相关概念视频
Cancer Therapies
8.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)